Brought to you by 
Genzyme to help develop Osiris' Prochymal
Aug 2007
Executive Summary
Genzyme and Osiris (stem cell therapies) have signed an alliance focused on the creation of drugs for radiological emergencies, including nuclear terrorism strikes.
Deal Industry
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
- Intra-Biotech Deal
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com